3,5-dichloro-N-(4-fluorobenzyl)-2-hydroxy-N-(4-(4-(pyrazine-2-yl)piperazine-1-carbonyl)benzyl)benzenesulfonamide | 1201661-79-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 3,5-dichloro-N-(4-fluorobenzyl)-2-hydroxy-N-(4-(4-(pyrazine-2-yl)piperazine-1-carbonyl)benzyl)benzenesulfonamide
• 英文别名: 3,5-dichloro-N-[(4-fluorophenyl)methyl]-2-hydroxy-N-[[4-(4-pyrazin-2-ylpiperazine-1-carbonyl)phenyl]methyl]benzenesulfonamide
• CAS: 1201661-79-1
• 化学式: C₂₉H₂₆Cl₂FN₅O₄S
• 分子量: 630.527
• InChiKey: MXHCHTYGBFEAAC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  42
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  115
• 氢给体数：
  1
• 氢受体数：
  9

文献信息

• HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS
  申请人：Kim kyoung S

  公开号：US20110294793A1

  公开（公告）日：2011-12-01

  The present invention provides compound of Formula (I): or a stereoisomer, tautomer, salt or solvate thereof, wherein the variables are defined herein. The compounds of formula (I) are inhibitors of Bcl-2 family antiapoptotic proteins, compositions containing the compounds and methods of treating diseases using the compounds.

  本发明提供了式（I）的化合物：或其立体异构体，互变异构体，盐或溶剂化物，其中变量在此定义。式（I）的化合物是Bcl-2家族抗凋亡蛋白的抑制剂，包含该化合物的组合物以及使用该化合物治疗疾病的方法。
• Chemical entities that kill senescent cells for use in treating age-related disease
  申请人：Unity Biotechnology, Inc.

  公开号：US10195213B2

  公开（公告）日：2019-02-05

  Disclosed herein are compounds that are effective for treatment of various disease states associated with senescence. The disclosed compounds can be used to eliminate senescent cells for disease treatment. The dosing of the compounds includes both single administration and regimens of cycling dosages.

  本文公开的化合物可有效治疗与衰老有关的各种疾病状态。所公开的化合物可用于消除衰老细胞以治疗疾病。化合物的给药方式包括单次给药和循环给药。
• COMPOUNDS AND THERAPEUTIC USES
  申请人：Unity Biotechnology, Inc.

  公开号：US20170281649A1

  公开（公告）日：2017-10-05

  Disclosed herein are compounds that are effective for treatment of various disease states associated with senescence. The disclosed compounds can be used to eliminate senescent cells for disease treatment. The dosing of the compounds includes both single administration and regimens of cycling dosages.
• US8501992B2
  申请人：——

  公开号：US8501992B2

  公开（公告）日：2013-08-06